D. Boral Capital restated their buy rating on shares of Invivyd (NASDAQ:IVVD - Free Report) in a research note released on Thursday morning,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.
IVVD has been the topic of several other reports. HC Wainwright lowered their target price on Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a research note on Wednesday, October 30th. Finally, Morgan Stanley decreased their target price on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Invivyd presently has an average rating of "Buy" and a consensus price target of $7.89.
Check Out Our Latest Research Report on Invivyd
Invivyd Trading Down 4.4 %
NASDAQ IVVD traded down $0.03 during trading hours on Thursday, hitting $0.67. The company's stock had a trading volume of 597,943 shares, compared to its average volume of 635,811. The company's 50-day simple moving average is $0.97 and its two-hundred day simple moving average is $1.22. Invivyd has a 52 week low of $0.67 and a 52 week high of $5.20. The company has a market capitalization of $80.17 million, a PE ratio of -0.36 and a beta of 0.65.
Hedge Funds Weigh In On Invivyd
A number of institutional investors have recently made changes to their positions in IVVD. Vanguard Group Inc. lifted its position in Invivyd by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company's stock worth $11,594,000 after buying an additional 97,496 shares during the last quarter. State Street Corp raised its stake in shares of Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company's stock worth $1,039,000 after acquiring an additional 35,904 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock worth $866,000 after acquiring an additional 31,992 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company's stock valued at $745,000 after purchasing an additional 474,301 shares in the last quarter. Finally, Duquesne Family Office LLC bought a new position in shares of Invivyd during the 2nd quarter valued at $629,000. Institutional investors own 70.36% of the company's stock.
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Read More
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
